Kolek Antonín, Prasko Jan, Ociskova Marie, Holubova Michaela, Vanek Jakub, Grambal Ales, Slepecky Milos
Department of Psychiatry, Faculty of Medicine and Dentistry, University Palacky Olomouc, University Hospital, 77520 Olomouc, Czech Republic.
Department of Psychology Sciences, Faculty of Social Science and Health Care, Constantine the Philosopher University in Nitra, Slovakia.
Neuro Endocrinol Lett. 2019 Dec;40(6):271-283.
A combination of antidepressants with the cognitive-behavioural therapy showed effectiveness in treatment-resistant patients with panic disorder. This prospective study intended to establish how childhood adverse experiences, self-stigma, dissociation, and severity of psychopathology influence the effectiveness of combined cognitive-behavioural therapy and pharmacotherapy in patients with treatment-resistant panic disorder.
One hundred and ten patients were included into the study and one hundred five subjects finished the study. After admission, the subjects were assessed during the first two days of hospitalization. Rating scales were administered before the beginning of the cognitive behavioural therapy (measurement-1) and at the end of the treatment which was after six weeks (measurement-2). Patients with panic disorder were treated using a combination of group cognitive-behavioural therapy and antidepressants. The usual antidepressant dosage range was used. Before admission to intensive cognitive behavioural therapy program, the patients were unsuccessfully treated by antidepressants for minimum 3 months, which defined them as pharmacoresistant.
Hospitalized pharmacoresistant patients with panic disorder improved significantly throughout the 6-week intensive CBT program in all measurements that assessed the overall severity of the disorder, the degree of general anxiety and depression and the severity of specific symptoms of panic disorder and agoraphobia. The rate of improvement was negatively related to sexual abuse in childhood, presence of comorbid personality disorder, and positively with the severity of the disorder at the beginning, and the level of self-stigma at the beginning of treatment. Improvement in symptoms correlates significantly with decreasing of dissociation during the treatment.severity of depressive symptoms. The earlier development of the disorder is linked to higher score in childhood adverse events, higher level of dissociation and pathological dissociation, and higher level of self-stigma.
Our prospective study discovers importance of the role of adverse childhood experiences, self-stigma, dissociation and comorbid personality disorder in effectiveness of combined cognitive-behavioural therapy and pharmacotherapy treatment in patients with treatment-resistant panic disorder.
抗抑郁药与认知行为疗法相结合,对难治性惊恐障碍患者显示出疗效。这项前瞻性研究旨在确定童年不良经历、自我污名化、分离以及精神病理学严重程度如何影响难治性惊恐障碍患者认知行为疗法与药物疗法联合治疗的效果。
110名患者纳入研究,105名受试者完成研究。入院后,在住院的前两天对受试者进行评估。在认知行为疗法开始前(测量1)和治疗结束时(六周后,测量2)使用评定量表。惊恐障碍患者采用团体认知行为疗法和抗抑郁药联合治疗。使用常规抗抑郁药剂量范围。在进入强化认知行为治疗项目之前,患者使用抗抑郁药治疗至少3个月未成功,这将他们定义为药物抵抗性患者。
在评估疾病总体严重程度、一般焦虑和抑郁程度以及惊恐障碍和广场恐惧症特定症状严重程度的所有测量中,住院的药物抵抗性惊恐障碍患者在为期6周的强化认知行为疗法项目中均有显著改善。改善率与童年期性虐待、共病性人格障碍呈负相关,与治疗开始时疾病的严重程度和自我污名化水平呈正相关。症状的改善与治疗期间分离的减少、抑郁症状的严重程度显著相关。疾病的早期发展与童年不良事件得分较高、分离和病理性分离水平较高以及自我污名化水平较高有关。
我们的前瞻性研究发现,童年不良经历、自我污名化、分离和共病性人格障碍在难治性惊恐障碍患者认知行为疗法与药物疗法联合治疗效果中所起作用的重要性。